Clinical Characteristics and Treatment Results of Pediatric Relapsed/Refractory Non-Hodgkin’s Lymphomas

Oncogematologiya - Russian Federation
doi 10.17650/1818-8346-2018-13-2-21-31
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Publishing House ABV Press

Related search

Non‐Hodgkin’s Lymphomas

Bone Marrow Transplantation
TransplantationHematology
2000English

Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas

Klinicheskaya Onkogematologiya/Clinical Oncohematology
OncologyHematology
2016English

Incidence of Hodgkin’s & Non Hodgkin’s Lymphomas and Comparison of Their Hematological Parameters

Journal of Medical Science And clinical Research
2018English

Targeted Drug Brentuximab Vedotin for Treatment of Relapsed or Refractory Cd30-Positive Hodgkin’s Lymphoma

Malignant tumours
2017English

Case Series of Nivolumab Treatment in Patients With Relapsed/Refractory Hiv-Related Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

The Treatment of Relapsed or Refractory Intermediate Grade Non-Hodgkin’s Lymphoma With Autologous Bone Marrow Transplantation Followed by Cyclosporine and Interferon

Bone Marrow Transplantation
TransplantationHematology
1997English

Clinical Outcomes From Venetoclax Based Therapy in Patients With Relapsed/Refractory B-Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

High Expression of Cathepsin D in Non-Hodgkin’s Lymphomas Negatively Impacts on Clinical Outcome

Disease Markers
BiochemistryMedicineClinical BiochemistryMolecular BiologyGenetics
2010English

Treatment of Relapsed and Refractory T-Cell Lymphomas: First Pavlov State Medical University of Saint-Petersburg Experience

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy